172 related articles for article (PubMed ID: 30707578)
1. Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).
Guerrero M; Urbano M; Kim EK; Gamo AM; Riley S; Abgaryan L; Leaf N; Van Orden LJ; Brown SJ; Xie JY; Porreca F; Cameron MD; Rosen H; Roberts E
J Med Chem; 2019 Feb; 62(4):1761-1780. PubMed ID: 30707578
[TBL] [Abstract][Full Text] [Related]
2. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology.
Margolis EB; Wallace TL; Van Orden LJ; Martin WJ
PLoS One; 2020; 15(12):e0232864. PubMed ID: 33373369
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
[TBL] [Abstract][Full Text] [Related]
5. Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.
Xie JY; De Felice M; Kopruszinski CM; Eyde N; LaVigne J; Remeniuk B; Hernandez P; Yue X; Goshima N; Ossipov M; King T; Streicher JM; Navratilova E; Dodick D; Rosen H; Roberts E; Porreca F
Cephalalgia; 2017 Jul; 37(8):780-794. PubMed ID: 28376659
[TBL] [Abstract][Full Text] [Related]
6. Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242).
Verhoest PR; Basak AS; Parikh V; Hayward M; Kauffman GW; Paradis V; McHardy SF; McLean S; Grimwood S; Schmidt AW; Vanase-Frawley M; Freeman J; Van Deusen J; Cox L; Wong D; Liras S
J Med Chem; 2011 Aug; 54(16):5868-77. PubMed ID: 21744827
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.
Owens SM; Pollard GT; Howard JL; Fennell TR; Snyder RW; Carroll FI
ACS Chem Neurosci; 2016 Dec; 7(12):1737-1745. PubMed ID: 27700049
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents.
Carroll FI; Gichinga MG; Kormos CM; Maitra R; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA
Bioorg Med Chem; 2015 Oct; 23(19):6379-88. PubMed ID: 26342544
[TBL] [Abstract][Full Text] [Related]
9. Species differences in the effects of the κ-opioid receptor antagonist zyklophin.
Sirohi S; Aldrich JV; Walker BM
Alcohol; 2016 Mar; 51():43-9. PubMed ID: 26992699
[TBL] [Abstract][Full Text] [Related]
10. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
11. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
[TBL] [Abstract][Full Text] [Related]
12. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.
Jackson KJ; Jackson A; Carroll FI; Damaj MI
Neuropharmacology; 2015 Oct; 97():270-4. PubMed ID: 26044637
[TBL] [Abstract][Full Text] [Related]
13. Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
Carlezon WA; Krystal AD
Depress Anxiety; 2016 Oct; 33(10):895-906. PubMed ID: 27699938
[TBL] [Abstract][Full Text] [Related]
14. Alleviation of Cocaine Withdrawal and Pertinent Interactions between Salvinorin-Based Antagonists and Kappa Opioid Receptor.
Akins NS; Salahuddin MF; Pandey P; Kim SJ; Mahdi F; Khan MIH; Moss EM; Worth CJ; Keane MM; Chittiboyina AG; Doerksen RJ; Paris JJ; Le HV
ACS Chem Neurosci; 2023 Mar; 14(5):958-976. PubMed ID: 36795782
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.
Zheng Z; Huang XP; Mangano TJ; Zou R; Chen X; Zaidi SA; Roth BL; Stevens RC; Katritch V
J Med Chem; 2017 Apr; 60(7):3070-3081. PubMed ID: 28339199
[TBL] [Abstract][Full Text] [Related]
16. Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).
Kormos CM; Ondachi PW; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA; Fennell TR; Snyder RW; Carroll FI
J Med Chem; 2018 Sep; 61(17):7546-7559. PubMed ID: 30032602
[TBL] [Abstract][Full Text] [Related]
17. Structure-Activity Relationships of [des-Arg
Ramos-Colon CN; Lee YS; Remesic M; Hall SM; LaVigne J; Davis P; Sandweiss AJ; McIntosh MI; Hanson J; Largent-Milnes TM; Vanderah TW; Streicher J; Porreca F; Hruby VJ
J Med Chem; 2016 Nov; 59(22):10291-10298. PubMed ID: 27797517
[TBL] [Abstract][Full Text] [Related]
18. Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation.
Melief EJ; Miyatake M; Carroll FI; Béguin C; Carlezon WA; Cohen BM; Grimwood S; Mitch CH; Rorick-Kehn L; Chavkin C
Mol Pharmacol; 2011 Nov; 80(5):920-9. PubMed ID: 21832171
[TBL] [Abstract][Full Text] [Related]
19. N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.
Béguin C; Potter DN; Dinieri JA; Munro TA; Richards MR; Paine TA; Berry L; Zhao Z; Roth BL; Xu W; Liu-Chen LY; Carlezon WA; Cohen BM
J Pharmacol Exp Ther; 2008 Jan; 324(1):188-95. PubMed ID: 17951511
[TBL] [Abstract][Full Text] [Related]
20. Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans.
Chang C; Byon W; Lu Y; Jacobsen LK; Badura LL; Sawant-Basak A; Miller E; Liu J; Grimwood S; Wang EQ; Maurer TS
AAPS J; 2011 Dec; 13(4):565-75. PubMed ID: 21847689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
